News and Events

BioNet announces the results of pivotal study evaluating Boostagen and Pertagen are published in the Lancet Infectious Diseases.

The new TdaP(PTgen/FHA) vaccine is safe and induces higher pertussis responses 28 days after vaccination than does the available licensed Tdap booster vaccine. Results of our trial led to the licensure of new acellular pertussis vaccines containing genetically inactivated pertussis toxin in Thailand. The availability of recombinant monovalent pertussis vaccines that induce high antibody responses provides the medical community and consumers with the opportunity to vaccinate against pertussis when immunisation against diphtheria and tetanus is not required or not desired. Studies are underway to pave the way for licensure studies of this acellular pertussis vaccine in other countries.

Read more

New acellular pertussis vaccine may solve waning immunogenicity problem

MADRID – A novel, monovalent, acellular pertussis vaccine containing a recombinant, genetically inactivated pertussis toxin displayed markedly greater sustained immunogenicity than the widely used Sanofi Pasteur Tdap, known as Adacel, which is used as a booster vaccination of adolescents and young adults, in a pivotal phase 3, randomized trial, Simonetta Viviani, MD, reported at the annual meeting of the European Society for Paediatric Infectious Diseases.

Read more

BioNet to present at the Biotechnology International Congress (BIC) 2015, Bangkok, Thailand.

BioNet-Asia (BioNet) today announced that its Chief Scientific Officer, Dr. Jean Petre gave a keynote presentation on "Vaccine Development in Developing Countries" at the Biotechnology International Congress (BIC) 2015. This year, the theme for the congress was focused on "Biotechnology for Healthy Society" and on this occasion, Invited speaker Prof. Watanalai Panbangred (Mahidol University) also presented on "Genetic manipulation of bacterial strains for vaccine development". BioNet also chose BIC 2015 to present the phase I/II clinical trial results of its Recombinant Acellular Pertussis Vaccine. The trial was conducted by Assoc. Prof. Chukiat Sirivichayakul to assess the safety and immunogenicity of BioNet's Vaccine, the first of its type, developed and manufactured in Thailand. Dr Hong Thai Pham, BioNet's CEO, indicated that "we are very pleased with the clinical phase I/II results which are very encouraging as we undertake the phase II/III of our aP vaccine".

The BIC 2015 was organized by The Thai Society for Biotechnology (TSB) during 9th-10th September, 2015 at Bangkok International Trade & Exhibition Centre (BITEC), Thailand. "BIC has been established with the main aim of sharing the research advancement and experience among scientist in biotechnology and related areas". (Source: http://www.biotec.or.th/tsb/index.php/8-2015-01-06-02-24-29/34-biotechnology-international-congress-bic-2015).

About BioNet-Asia
BioNet-Asia is an independent vaccine company with a focus on technological innovation and global market access. In its vaccine manufacturing plant in Thailand, BioNet is developing a broad pipeline of products in R&D and clinical stages, such as acellular recombinant pertussis, Dengue and Hepatitis B vaccines. The company also offers the technology to produce the Hib meningitis vaccine, now commercialized as a pentavalent vaccine in Asia. For more information, please visit www.bionet-asia.com.

Download

BioNet Attended the Maternal Immunization Stakeholder Convening Organized by the Bill and Melinda Gates Foundation, in Berlin, Germany

Every year, newborn deaths account nearly 3 million within the first month of life, most from preventable causes. It accounts for 44 precents of all deaths among children under the age of five globally. More than a third of these newborn die on their first day of life. In order to intensify the efforts towards improving newborn health, the global health community is actively working to identify innovative ways to address this important area of need. Maternal immunization has emerged as a promising intervention strategy to prevent disease in newborn as well as their mothers. By providing vaccinations to pregnant women, antibodies are transferred from the mother to the fetus and can provide protection for the baby for several months after birth as well as early appearance of mucosal antibodies in breast milk.

In 2011 the US Advisory Committee on Immunization Practice (ACIP) has marked the beginning of universal immunization programs during pregnancy by recommending maternal TdaP vaccination for women who has not been vaccinated before to protect against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).

Recently, the Bill and Melinda Gates Foundation (BMGF) has organized the maternal immunization stakeholder convening in Berlin, Germany to bring together global health stakeholders to better understand the challenges, knowledge gaps and potential impact of maternal immunization. Mr. Vitoon Vonghangool, President of BioNet-Asia (BioNet), Dr. Boonchai Somboonsook, Secretary-General of Food and Drug Administration of Thailand (TFDA), and Dr. Tawee Chotpitayasunondh, Senior Medical Officer and a paediatric infectious diseases specialist consultant at the Queen Sirikit National Institute of Child Health, Ministry of Public Health, Thailand have been invited. BioNet as one of stakeholder has been conducting research and development of Recombinant Pertussis Vaccine. The recombinant DNA technology was used to eliminate the need for chemical inactivation of the vaccine components and produces more native and active ingredients. Pertussis is a highly contagious vaccine preventable respiratory infectious disease worldwide. It occurs at any age, but the high incidence of pertussis cases among young infants reflect non-protective levels of maternal pertussis-related antibodies, increased exposure to pertussis, or a combination of both.

"A major goal of this stakeholder convening was to facilitate coordination and collaboration between the Vaccine and Maternal, Newborn and Child Health (MNCH) communities, as well as among stakeholders across functions. It's addressed the need to align on key next steps toward the eventual implementation of maternal immunization in low- and low-middle-income countries. This convening involved major donors and more than 100 leaders from academia, vaccine manufacturing, regulatory agencies, multilateral organizations and representatives of the Minister of Health from Africa, Asia and South America." (Source: Maternal Immunization: Partners Convene to Align on Way Forward by Ajoke Sobanjo-ter Meulen)

Download

BioNet collaborated on new brand Rabies vaccine for the Thai Market

See more information

Video

BioNet attended ThaiTECH for the Drug Development Part II: Current Situations & Challenges in Thailand

See more information

Video

BioNet-Asia, The Queen Saovabha Memorial Institute (QSMI) of the Thai Red Cross Society and Liaoning Cheng Da Bioechnology (CDBIO) have been collaborating to manufacture the next-generation highly purified cell culture rabies vaccine in Thailand

See more information

Video

BioNet-Asia present at BioJapan 2014

BioNet-Asia will be at BioJapan 2014 in Yokohama from 15th-17th October 2014. BioNet senior management will present the company activities and provide a clinical update on its lead development program. BioNet has completed its phase I/II clinical trial evaluating two Pertussis Vaccines using BioNet proprietary recombinant pertussis toxin.

See more information about BioNet R&D Pipeline
See more information about BioJapan 2014

Symposium on Building Vaccine Development Capacity in Thailand

On the occasion of its 10th?anniversary, BioNet organized a Vaccine Symposium in collaboration with the National Vaccine Committee Office, Thailand on January 21, 2011.

Academic partnerships for developing conjugate vaccines, the Cape Town experience

(Prof.Neil Ravenscroft, University of Cape Town)

New approaches to Dengue vaccine development

(Assoc.Prof.Nopporn Sittisombut, Chiang Mai University)

Role of NVCO in supporting vaccine development and production in Thailand

(Dr.Charung Muangchana, National Vaccine Institute)

Vaccine R&D opportunities for developing countries

(Dr.Jean O.A. Petre, Technical and Scientific Director, BioNet-Asia)

แนวทางการพัฒนานักวิจัยเพื่อรองรับความต้องการของภาคอุตสาหกรรมในอนาคต

(Prof.Dr.Amaret Bhumiratana, The Thailand Research Fund (TRF)

สิทธิประโยชน์และการส่งเสริมการลงทุนสำหรับกิจการวิจัยและพัฒนา

(Dr.Ratchanee Wattanawisitporn, Office of the Board of Investment)